Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines

Abstract

CD40 is a potent activating receptor expressed on antigen-presenting cells (APCs) of the immune system. CD40 regulates many aspects of B and T cell immunity via interaction with CD40L expressed on activated T cells. Targeting antigens to CD40 via agonistic anti-CD40 antibody fusions promotes both humoral and cellular immunity, but current anti-CD40 antibody-antigen vaccine prototypes require co-adjuvant administration for significant in vivo efficacy. This may be a consequence of dulling of anti-CD40 agonist activity via antigen fusion. We previously demonstrated that direct fusion of CD40L to anti-CD40 antibodies confers superagonist properties. Here we show that anti-CD40-CD40L-antigen fusion constructs retain strong agonist activity, particularly for activation of dendritic cells (DCs). Therefore, we tested anti-CD40-CD40L antibody fused to antigens for eliciting immune responses in vitro and in vivo. In PBMC cultures from HIV-1-infected donors, anti-CD40-CD40L fused to HIV-1 antigens preferentially expanded HIV-1-specific CD8+ T cells versus CD4+ T cells compared to analogous anti-CD40-antigen constructs. In normal donors, anti-CD40-CD40L-mediated delivery of Influenza M1 protein elicited M1-specific T cell expansion at lower doses compared to anti-CD40-mediated delivery. Also, on human myeloid-derived dendritic cells, anti-CD40-CD40L-melanoma gp100 peptide induced more sustained Class I antigen presentation compared to anti-CD40-gp100 peptide. In human CD40 transgenic mice, anti-CD40-CD40L-HIV-1 gp140 administered without adjuvant elicited superior antibody responses compared to anti-CD40-gp140 antigen without fused CD40L. In human CD40 mice, compared to the anti-CD40 vehicle, anti-CD40-CD40L delivery of Eα 52-68 peptide elicited proliferating of TCR I-Eα 52-68 CD4+ T cells producing cytokine IFNγ. Also, compared to controls, only anti-CD40-CD40L-Cyclin D1 vaccination of human CD40 mice reduced implanted EO771.LMB breast tumor cell growth. These data demonstrate that human CD40-CD40L antibody fused to antigens maintains highly agonistic activity and generates immune responses distinct from existing low agonist anti-CD40 targeting formats. These advantages were in vitro skewing responses towards CD8+ T cells, increased efficacy at low doses, and longevity of MHC Class I peptide display; and in mouse models, a more robust humoral response, more activated CD4+ T cells, and control of tumor growth. Thus, the anti-CD40-CD40L format offers an alternate DC-targeting platform with unique properties, including intrinsic adjuvant activity.

Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2

“…The regulation of vaccine immune response is triggered by Toll-like receptors (TLRs) on DCs through the downstream NF-κB signaling pathway [ 64 , 65 ]. Mature DCs express MHC molecules as well as co-stimulatory molecules bind to TCR and activate T cells [ 66 , 67 ], which differentiate into T follicular helper cells (Tfh), regulatory T cells (Tregs), and cytotoxic or “killer” T cells (Tc) [ 68 ]. Then naive B cells undergo differentiation into plasma cells and memory B cells, ultimately contributing to the formation of GCs [ 34 ].…”

Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine

“…TLRs on DCs are the most widely studied PPRs, which can trigger the downstream NF-κB signaling pathway leading to the induction of pro-inflammatory cytokines and regulation of the vaccine immune response, which is also known as the TLRs signaling pathway [38] , [39] . MHC molecules and co-stimulatory molecules expressed by mature DCs bind to the TCR on the surface of T cells and activate T cells [40] , [41] . Then activated T cells through T cell receptor and NF - κ B signaling pathway promote the production of cytokines [42] , [43] , and differentiate into helper T cells (Th), regulatory T cells (Tregs) and cytotoxic or “killer” T cells (Tc).…”

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques

“…This was partly driven by that agonistic CD40 antibodies have distinct characteristics in mice and humans [ 16 ] and human FcγRs are different from mouse FcγRs [ 57 ]. Previous studies have mostly used human CD40 transgenic (hCD40Tg) mice [ 42 , 58 ], hCD40Tg FcγRIIb-/- mice [ 55 ], hCD40Tg FcγR-/- mice [ 46 ] or hCD40Tg/mFcgr2b-/-/hFcgr2b ± mice [ 45 ]. However, it has been proposed that only humanized CD40/FcγR mice can provide the correct in vivo environment for evaluating human CD40 antibodies [ 20 ].…”